Search

UCB SA

Suletud

SektorTervishoid

211.1 1.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

207.4

Max

212.6

Põhinäitajad

By Trading Economics

Sissetulek

28M

1.1B

Müük

16M

4.3B

P/E

Sektori keskmine

18.561

56.597

Aktsiakasum

5.7

Dividenditootlus

0.69

Kasumimarginaal

26.019

Töötajad

9,000

EBITDA

587M

1.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.69%

2.18%

Turustatistika

By TradingEconomics

Turukapital

-6.7B

40B

Eelmine avamishind

209.51

Eelmine sulgemishind

211.1

Uudiste sentiment

By Acuity

24%

76%

33 / 339 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. sept 2026, 23:51 UTC

News

Rimini Street shares lower in after-market trading despite announcing a partnership with Datacom to support Oracle and SAP software in Australia and New Zealand.

14. sept 2026, 23:51 UTC

News

Shares of Gartner Inc are lower in after-market hours following unusual weakness, despite the recent launch of its IT Symposium/Xpo conference highlighting key technology trends.

14. sept 2026, 23:41 UTC

News

Autodesk shares are lower in after-market hours following a Neutral rating from Cantor Fitzgerald, which set a price target of $215.00.

14. sept 2026, 23:36 UTC

Correlated Moves
News

ATI Inc will highlight aerospace opportunities at the Morgan Stanley Laguna Conference on September 17, 2026. Shares were higher in after-market trading.

14. sept 2026, 23:36 UTC

News

NextEra Energy plans to enhance its merger proposal with Dominion Energy by extending bill credits and creating 600 new jobs in Virginia. Shares rose in after-market hours.

14. sept 2026, 23:31 UTC

News

Northrop Grumman Corp received a $34,388,301 contract modification for military helicopter components. Shares declined in after-market trading despite the news.

14. sept 2026, 23:31 UTC

News
Social Media

Lockheed Martin secured over $1.3 billion in defense contracts from the U.S. Department of War, with shares trading higher in after-market hours.

14. sept 2026, 23:31 UTC

News
Social Media

Scholar Rock Holding Corp shares declined in after-market trading following FDA approval of Isembyld, amid concerns over pricing and treatment risks.

14. sept 2026, 23:26 UTC

Correlated Moves
News

NXP Semiconductors NV gains in after-market trading, supported by its focus on physical AI and a shift to asset-light manufacturing for automotive revenue.

14. sept 2026, 23:21 UTC

Event
News

Children's Place reported second-quarter net sales of $241.8 million, missing estimates, and shares fell sharply in after-hours trading following the results.

14. sept 2026, 23:21 UTC

Correlated Moves
News

The U.S. dollar strengthens against major currencies, boosting USD/DKK amid expectations of a Fed interest rate hike following higher inflation figures.

14. sept 2026, 23:16 UTC

News

Walt Disney Co is requiring more remote employees to return to the office four days a week. Shares are little changed in after-market trading.

14. sept 2026, 23:11 UTC

News

Leonardo DRS rises in after-market on Guggenheim Buy rating.

14. sept 2026, 23:11 UTC

Correlated Moves
News

The U.S. dollar strengthens against major currencies, including USD/CZK, amid expectations of a Federal Reserve interest rate hike following rising inflation.

14. sept 2026, 23:06 UTC

Correlated Moves
News

Morgan Stanley's shares are advancing in after-market trading, influenced by Goldman Sachs' performance amid rising crude oil prices and supply concerns.

14. sept 2026, 23:06 UTC

News

Uranium Energy Corp shares are lower in after-market hours amid rising crude oil prices and concerns over future uranium supply dynamics from Saudi Arabia's recent discoveries.

14. sept 2026, 23:06 UTC

News

Marathon Petroleum shares are higher in after-market trading following recognition at the Fleet Safety Awards, reflecting positive sentiment amid global fuel supply constraints.

14. sept 2026, 23:06 UTC

News
Social Media

Eli Lilly's Foundayo captures over 30% of new U.S. obesity patients, boosting shares higher in after-market hours amid strong demand for oral treatments.

14. sept 2026, 23:06 UTC

News

NVIDIA shares are higher in after-hours trading following President Trump's remarks dismissing AI regulation concerns during a call with CEO Jensen Huang.

14. sept 2026, 23:06 UTC

News

Target Corp appointed Mark Weinstein as Chief Marketing and Guest Experience Officer, a move aimed at enhancing consumer engagement. Shares are trading higher in after-market hours.

14. sept 2026, 23:06 UTC

News

Accenture PLC shares are lower in after-market hours following a $25 million settlement over discrimination claims. Broader market pressures also weigh on the stock.

14. sept 2026, 23:06 UTC

News

Ethereum is trading higher amid positive market sentiment and rising crude oil prices. The Federal Reserve's expected interest rate hike adds complexity to the market.

14. sept 2026, 23:06 UTC

News

Bitcoin is trading higher amid rising crude oil prices and inflation concerns. U.S. Treasury yields reaching 5% also impact investor sentiment towards the digital asset.

14. sept 2026, 23:06 UTC

News

Ethereum is trading higher amid positive sentiment, despite intraday volatility. Crude oil price surges and upcoming Fed rate hike add complexity to market dynamics.

14. sept 2026, 23:06 UTC

News

Bitcoin is trading higher amid rising crude oil prices and heightened inflation concerns. U.S. Treasury yields have also reached 5%, impacting investor sentiment.

14. sept 2026, 23:01 UTC

News

BlackRock shares are rising in after-market trading following CEO Larry Fink's participation in a summit aimed at attracting C$1 trillion in global investments to Canada.

14. sept 2026, 23:01 UTC

News

Dave and Buster's Entertainment shares fell after the company reported a $12.5 million net loss and revenue that missed expectations during after-market hours.

14. sept 2026, 23:01 UTC

News

Radiant Logistics reports fourth-quarter revenue of $261.4 million, an 18.5% increase, and net income of $7.5 million, driving shares higher in after-market trading.

14. sept 2026, 23:01 UTC

News

Leidos Holdings has secured an $875 million Navy contract for network management, boosting shares in after-market hours.

14. sept 2026, 23:01 UTC

Event
News

Enova International withdrew its acquisition applications for Grasshopper Bancorp, leading shares lower in after-market hours. The company reaffirmed its guidance for 2026.

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

33 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
help-icon Live chat